IMO, the stock dropped because of profit taking by investors disappointed that a buyout was not announced. Going way back, I have always felt Barron's seems to work with shorts...LOL
Anyone bidding for BMY already has a number in mind, and it would be a percentage premium over current levels. I always guessed about 80 but that was just taking the average percentage bump of mega mergers when the stock was at 59 prior to the last run BMY went on.
Went in for more options, even as low as 62.5... Very heavy AH trading on the Merc news. Selling in Merc overreaction.
Recent BMY News
- KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 04/08/2024 03:30:00 PM
- Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy • Business Wire • 04/05/2024 01:05:00 PM
- European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) • Business Wire • 04/03/2024 12:08:00 AM
- Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals • Business Wire • 04/02/2024 10:59:00 AM
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… • Business Wire • 03/28/2024 08:05:00 PM
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease • Business Wire • 03/28/2024 08:01:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde • Business Wire • 03/26/2024 06:25:00 PM
- Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes • Business Wire • 03/26/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio • Business Wire • 03/25/2024 12:00:00 PM
- Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma • Business Wire • 03/20/2024 08:45:00 PM
- Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma • Business Wire • 03/20/2024 10:59:00 AM
- Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign • Business Wire • 03/19/2024 10:59:00 AM
- Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio • Business Wire • 03/18/2024 12:44:00 PM
- FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy • Business Wire • 03/15/2024 10:27:00 PM
- U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) • Business Wire • 03/15/2024 01:35:00 AM
- Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024 • Business Wire • 03/11/2024 08:16:00 PM
- U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 03/07/2024 07:23:00 PM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 03/06/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:57:57 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:52:54 PM
- Bristol Myers Squibb Announces Dividend • Business Wire • 03/01/2024 09:16:00 PM
- Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis • Business Wire • 02/29/2024 11:59:00 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM